SEARCH RESULTS FOR: 【溦信88931766】i换脸张子枫11V4G最全所有视频资源全部作品合集.ldb(18171 results)
Only the first 10,000 results were returned. Filter these results or refine your query. Some pre-built queries with more than 10,000 results are available for download.
Used in sera screening for determining the presence of serum HLA alloantibodies for HLA Class I and II specificities with a complement dependent microlymphocytotoxic assay.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018751 ()
LCT1W60S
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018713 ()
LATP240
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018706 ()
LATP1HD
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018690 ()
LATP140X2
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018683 ()
LATP140
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018676 ()
LATP1288
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018669 ()
LATP1240
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018652 ()
LATM20X5P
- HLA class I & II antibody screening IVD, kit, multiplex
The assay is designed for detection of potentially detrimental antibody against HLA antigens in the serum of pre- and post-transplant organ recipients.
ONE LAMBDA, INC.
N/A
In Commercial Distribution
- 00812117018645 ()
LATM120P
- HLA class I & II antibody screening IVD, kit, multiplex
Human lymphocytes for 6 detections of human HLA-ABC antibodies in the complement-dependent microlymphocytotoxicity test
Bio-Rad Medical Diagnostics GmbH
823300
Not in Commercial Distribution
- 07611969952939 ()
823300
- HLA class I antibody identification panel IVD, kit, complement-dependent cytotoxicity (CDC)
Human lymphocytes for 6 detections of human HLA-ABC antibodies in the complement-dependend microlymphocytotoxicity test
Bio-Rad Medical Diagnostics GmbH
823300
Not in Commercial Distribution
- 07611969965700 ()
- HLA class I antibody identification panel IVD, kit, complement-dependent cytotoxicity (CDC)
Anti-Beta 2 Glycoprotein Screen ELISA is a solid phase enzyme immunoassay employing native Beta-2glycoprotein I highly purified from human plasma for the combined quantitative and qualitative detection of IgA, IgG and IgM antibodies against Beta-2-glycoprotein I in human serum.
AMERICAN LABORATORY PRODUCTS COMPANY, LTD.
35-B2SHU-E01
Not in Commercial Distribution
- B24235B2SHUE010 ()
35-B2SHU-E01
- Beta-2-glycoprotein I antibody IVD, kit, enzyme immunoassay (EIA)
No Description
Roche Diagnostics GmbH
07475993190
In Commercial Distribution
- 07613336143155 ()
07475993190
- Insulin-like growth factor I (IGF1) IVD, control
No Description
Roche Diagnostics GmbH
07476108190
In Commercial Distribution
- 07613336129494 ()
07476108190
- Insulin-like growth factor I (IGF1) IVD, control
HemosIL AcuStar Anti-B2 Glycoprotein-I IgM
INSTRUMENTATION LABORATORY COMPANY
0009802016
In Commercial Distribution
- 08426950496984 ()
0009802016
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
HemosIL AcuStar Anti-B2 Glycoprotein-I IgG
INSTRUMENTATION LABORATORY COMPANY
0009802012
In Commercial Distribution
- 08426950496977 ()
0009802012
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
No Description
DIASORIN SPA
319133
In Commercial Distribution
- 08056771200172 ()
- Insulin-like growth factor I (IGF1) IVD, kit, chemiluminescent immunoassay
No Description
MONOBIND, INC.
13375-300
In Commercial Distribution
- 00816870024899 ()
- Width: 7.75 Inch
13375-300B
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
No Description
MONOBIND, INC.
13325-300
In Commercial Distribution
- 00816870024813 ()
- Width: 7.75 Inch
13325-300A
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
No Description
MONOBIND, INC.
13325-300
In Commercial Distribution
- 00816870024882 ()
- Width: 7.75 Inch
13325-300B
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
No Description
MONOBIND, INC.
13375-300
In Commercial Distribution
- 00816870024820 ()
- Width: 7.75 Inch
13375-300A
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
The DRG IGF-1 600 ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Insulin-like Growth Factor 1, IGF-1, in serum.
DRG Instruments Gesellschaft mit beschränkter Haftung
EIA-4140
Not in Commercial Distribution
- 00404847441406 ()
EIA-4140
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
The DRG Progesterone ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Progesterone in serum or plasma (EDTA, lithium heparin or citrate plasma)
DRG Instruments Gesellschaft mit beschränkter Haftung
EIA-1561
Not in Commercial Distribution
- 00404847415612 ()
EIA-1561
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
No Description
IMMUNODIAGNOSTIC SYSTEMS LIMITED
IS-3900
In Commercial Distribution
- 05060169690288 ()
- Insulin-like growth factor I (IGF1) IVD, kit, chemiluminescent immunoassay
INTENDED USE
For the detection and semi-quantitation of IgA anti-β2GPl antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome). For In Vitro Diagnostic Use.
SUMMARY OF THE TEST
Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine. High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals. Patients with positive reactions to both anti-phospholipid and anti-β2GPl assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgA anti-β2GPl antibodies have been reported in autoimmune patients. In addition, anti-β2GPl antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.
PRINCIPLE OF THE TEST
The test is an indirect ELISA. Diluted serum/plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β2GPl. After the removal of unbound serum or plasma proteins by washing, antibodies specific for human IgA, labeled with horseradish peroxidase (HRP), are added forming complexes with the β2GPl bound antibodies. Following another wash step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of anti-β2GPl antibodies. Results are obtained by reading the O.D. of each well in a spectrophotometer. Calibrator sera are provided, with the IgA anti-β2GPl antibody concentrations expressed in A units. Controls and patient results are determined from the calibration curve. Refer to product package insert.
CORGENIX MEDICAL CORPORATION
13372
In Commercial Distribution
- 00855360006199 ()
13372
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
INTENDED USE
For the detection and semi-quantitation of IgM anti-β2GPl antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome). For In Vitro Diagnostic Use.
SUMMARY OF THE TEST
Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine. High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals. Patients with positive reactions to both anti-phospholipid and anti-β2GPl assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgM anti-β2GPl antibodies have been reported in autoimmune patients. In addition, anti-β2GPl antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.
PRINCIPLE OF THE TEST
The test is an indirect ELISA. Diluted serum/plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β2GPl.. After the removal of unbound serum or plasma proteins by washing, antibodies specific for human IgM, labeled with horseradish peroxidase (HRP), are added forming complexes with the β2GPl bound antibodies. Following another wash step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of anti-β2GPl antibodies. Results are obtained by reading the O.D. of each well in a spectrophotometer. Calibrator sera are provided, with the IgM anti-β2GPl antibody concentrations expressed in M units. Controls and patient results are determined from the calibration curve. Refer to Product package insert.
CORGENIX MEDICAL CORPORATION
13371
In Commercial Distribution
- 00855360006182 ()
13371
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
INTENDED USE
For the detection and semi-quantitation of IgG anti-β2GPl antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome). For In Vitro Use Only.
SUMMARY AND EXPLANATION OF THE I TEST
Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine. High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals. Patients with positive reactions to both anti-phospholipid and anti-β2GPl assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgG anti-β2GPl antibodies have been reported in autoimmune patients. In addition, anti-β2GPl antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.
PRINCIPLE OF THE TEST
The test is s an indirect ELISA. Diluted serum/ plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β2GPl. After the removal of unbound serum/plasma proteins by washing, antibodies specific for human IgG, labeled with horseradish peroxidase (HRP), are added forming complexes with the β2GPl bound antibodies. Following another wash step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) as the chromogenic substrate. Color develops in the wells at intensity proportional to the serum concentration of anti-β2GPl antibodies. Results are obtained by reading the O.D. of each well in a spectrophotometer. Calibrator sera are provided, with the IgG anti-β2GPl antibody concentrations expressed in G units.. Controls and patient results are determined from the calibration curve. Refer to Product Package Insert.
CORGENIX MEDICAL CORPORATION
13370
In Commercial Distribution
- 00855360006175 ()
13370
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
INTENDED USE
For the detection and semi-quantitation of IgM anti-β2GPl antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome). For In Vitro Diagnostic Use.
SUMMARY OF THE TEST
Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic
phospholipids, including cardiolipin and phosphatidylserine. High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals. Patients with positive reactions to both anti-phospholipid and anti-β2GPl assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgM anti-β2GPl antibodies have been reported in autoimmune patients. In addition, anti-β2GPl antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.
PRINCIPLE OF THE TEST
The test is an indirect ELISA. Diluted serum/plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β2GPl. After the removal of unbound serum or plasma proteins by washing, antibodies specific for human IgM, labeled with horseradish peroxidase (HRP), are added forming complexes with the β2GPl bound antibodies. Following another wash step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of anti-β2GPl antibodies. Results are obtained by reading the O.D. of each well in a spectrophotometer. Calibrator sera are provided, with the IgM anti-β2GPl antibody concentrations expressed in M units. Controls and patient results are determined from the calibration curve. Refer to Product Package Insert.
CORGENIX MEDICAL CORPORATION
038-001
In Commercial Distribution
- 00855360006168 ()
038-001
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
INTENDED USE
For the detection and semi-quantitation of IgG anti-β2GPl antibodies in individuals with systemic lupus
erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome). For In Vitro Use Only.
SUMMARY OF THE TEST
Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine. High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals. Patients with positive reactions to both anti-phospholipid and anti-β2GPl assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgG anti-β2GPl antibodies have been reported in autoimmune patients. In addition, anti-β2GPl antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.
PRINCIPLE OF THE TEST
The test is an indirect ELISA. Diluted serum/plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β2GPl. After the removal of unbound serum or plasma proteins by washing, antibodies specific for human IgG, labeled with horseradish peroxidase (HRP), are added forming complexes with the β2GPl bound antibodies. Following another wash step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of anti-β2GPl antibodies. Results are obtained by reading the O.D. of each well in a spectrophotometer. Calibrator sera are provided, with the IgG anti-β2GPl antibody concentrations expressed in G units. Controls and patient results are determined from the calibration curve. Refer to Product Package Insert.
CORGENIX MEDICAL CORPORATION
037-001
In Commercial Distribution
- 00855360006151 ()
037-001
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
INTENDED USE
For the detection and semi-quantitation of IgA anti-β2GPl antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome). For In Vitro Use Only.
SUMMARY OF THE TEST
Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine. High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals. Patients with positive reactions to both anti-phospholipid and anti-β2GPl assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgA anti-β2GPl antibodies have been reported in autoimmune patients. In addition, anti-β2GPl antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.
PRINCIPLE OF THE TEST
The test is an indirect ELISA. Diluted serum/plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β2GPl. After the removal of unbound serum or plasma proteins by washing, antibodies specific for human IgA, labeled with horseradish peroxidase (HRP), are added forming complexes with the β2GPl bound antibodies. Following another wash step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of anti-β2GPl antibodies. Results are obtained by reading the O.D. of each well in a spectrophotometer. Calibrator sera are provided, with the IgA anti-β2GPl antibody concentrations expressed in A units. Controls and patient results are determined from the calibration curve. Refer to Product Package Insert.
CORGENIX MEDICAL CORPORATION
039-001
In Commercial Distribution
- 00855360006144 ()
039-001
- Anticardiolipin-B2-glycoprotein I complex antibody IVD, kit, enzyme immunoassay (EIA)
The Total IGF-I enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGF-I in serum, plasma and other biological fluids. This assay is intended for in vitro Diagnostic Use Only.
Ansh Labs, LLC
AL-121
In Commercial Distribution
- 00853592008295 ()
AL-121
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
The Total IGF-I enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGF-I in serum, plasma and other biological fluids. This assay is intended for in vitro diagnostic use only.
Ansh Labs, LLC
AL-121-i
In Commercial Distribution
- 00853592008066 ()
AL-121-i
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
Insulin-like growth factor I (IGF-I) 100 test kit
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD
11128584
In Commercial Distribution
- 00630414601243 ()
LKIGF1
- Insulin-like growth factor I (IGF1) IVD, kit, chemiluminescent immunoassay
Insulin-like growth factor I (IGF-I) 200 test kit
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD
11128543
In Commercial Distribution
- 00630414601236 ()
L2KIGF2
- Insulin-like growth factor I (IGF1) IVD, kit, chemiluminescent immunoassay
IGF-I - IMMULITE - RGT - 100 Tests
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD
10381403
In Commercial Distribution
- 00630414964041 ()
LKGF1
- Insulin-like growth factor I (IGF1) IVD, kit, chemiluminescent immunoassay
IGF-I - IMMULITE - RGT - 200 Tests
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD
10381448
In Commercial Distribution
- 00630414961538 ()
L2KGF2
- Insulin-like growth factor I (IGF1) IVD, kit, chemiluminescent immunoassay
IGF-1 ELISA
Diasource Immunoassays S.A. SA
KAP1581
In Commercial Distribution
- 05400569000209 ()
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
The DRG Progesterone ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Progesterone in serum or plasma (EDTA, lithium heparin or citrate plasma)
DRG Instruments Gesellschaft mit beschränkter Haftung
EIA-1561
In Commercial Distribution
- 04048474015614 ()
EIA-1561
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
The DRG IGF-1 600 ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Insulin-like Growth Factor 1, IGF-1, in serum.
DRG Instruments Gesellschaft mit beschränkter Haftung
EIA-4140
In Commercial Distribution
- 04048474041408 ()
EIA-4140
- Insulin-like growth factor I (IGF1) IVD, kit, enzyme immunoassay (EIA)
For Use with Factor VIII Antibody Screen and PakPlus
IMMUCOR GTI DIAGNOSTICS, INC.
403622
In Commercial Distribution
- 10888234500407 ()
403622
- HLA class I antibody screening IVD, reagent